For Immediate Release


Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Announces Participation in AMR Action Fund

Tokyo, Japan (July 10, 2020) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced its decision to participate in the Antimicrobial Resistance (hereafter, AMR) Action Fund (hereafter, AMR Action Fund) and contribute a total of 20 million US dollars to support the development of therapeutic agents for AMR infectious diseases.


AMR infectious diseases are resistant to existing antimicrobial agents, and without any countermeasures, more than 10 million people worldwide may die from AMR annually by 2050. The AMR Action Fund, established to promote the development of new antimicrobial agents for AMR, provides technical assistance and invests about 1 billion US dollars for small biotechnology companies to bring 2 to 4 new antibiotics to patients by 2030.


Daiichi Sankyo will participate in the AMR Action Fund to promote the development of innovative antimicrobial agents and contribute to the early resolution of global drug resistance issues.


AMR Action Fund
The AMR Action Fund was established to address drug-resistant bacteria through a partnership with the WHO (World Health Organization), EIB (European Investment Bank), and Welcome Trust based on the concept proposed by the IFPMA (International Federation of Pharmaceutical Manufacturers), BCR (Biopharmaceutical CEO Roundtable), and major pharmaceutical companies in the world.
The organization is funded by more than 20 of the world’s major pharmaceutical companies, charity organizations, development banks, and international organizations.


About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: